title: [Effects of controlled-release arsenic-trioxide-eluting stents on in-stent neointimal hyperplasia in coronary artery: experiment with dog model].
abstract: OBJECTIVE
  To study the safety and efficacy of controlled-release arsenic-trioxide (As(2)O(3))-eluting stents to reduce in-stent neointimal hyperplasia in coronary artery.
  
  
  METHODS
  As(2)O(3) was sprayed onto the stainless steel coated with polybutyl methacrylate/nano-silica and poly-lactide-co-glycolide so as to make the controlled-release As(2)O(3)-eluting stents with the As(2)O(3) concentrations of 0, 1.6, 2.4, and 3.2 microg/mm(2). Thirty adult dogs were randomly divided into 5 equal groups to undergo deployment of bare stent, coated stent, and As(2)O(3)-eluting stent of low dose (1.6 microg/mm(2)), medium dose (2.4, microg/mm(2)), and high dose (3.2 microg/mm(2)) into the left anterior descending artery or circumflex coronary artery respectively, and aspirin 250 mg/day was given 3 days before operation until 4 weeks after operation. Four weeks after the operation the dogs underwent angiography and then killed. The coronary artery, heart, liver, spleen, lung, kidney, and brain were taken out for pathological examination.
  
  
  RESULTS
  The mean injury scores were similar in all groups. The values of mean neointimal thickness of the high-, medium-, and low-dose groups were (0.14 +/- 0.05) mm, (0.15 +/- 0.04) mm, and (0.27 +/- 0.03 mm) respectively, all significantly lower than those of the coated stent and bare stent groups [(0.39 +/- 0.06) mm and (0.33 +/- 0.02) mm respectively, all P < 0.01], with significant differences between the high and medium groups and low dose group (both P < 0.01). The neointimal areas of the high, medium, and low dose groups were (1.09 +/- 0.11) mm(2), (1.33 +/- 0.10) mm(2), and (1.93 +/- 0.29) mm(2) respectively, all significantly smaller than those of the coated stent and bare stent groups [(2.44 +/- 0.15) mm(2) and (2.40 +/- 0.32) mm(2), all P < 0.01] with significant differences between the high and medium groups and low dose group (both P < 0.01). The stenosis rates of the high, medium, and low dose groups were (19.54 +/- 3.59)%, (22.18 +/- 3.3)%, and (36.22 +/- 5.17)% respectively, all significantly lower than those of the coated stent and bare stent groups [(50.39 +/- 3.03)%, and (46.88 +/- 5.85)% respectively, all P < 0.01] with significant differences between the high and medium groups and low dose group (both P < 0.01). The luminal areas of the high, medium, and low dose groups were (5.14 +/- 0.55) mm(2), (4.97 +/- 0.38) mm(2), and (3.75 +/- 0.39) mm(2) respectively, all significantly larger than those of the coated stent and bare stent groups [(2.62 +/- 0.22) mm(2) and (3.10 +/- 0.66) mm(2) respectively, both P < 0.01] with significant differences between the high and medium groups and low dose group (both P < 0.01). Pathological examination did not find intraintimal hemorrhage, medial and adventitial necrosis, aneurysm, thrombosis, and inflammatory cell infiltration in all groups.
  
  
  CONCLUSIONS
  Capable of inhibiting neointimal hyperplasia in the coronary arteries dose-dependently after implantation, controlled-release As(2)O(3)-eluting stents is safe and applicable in treating coronary diseases.
authors: Department of Cardiology, First People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200080, China.
authors: Jun-li
authors: JL
authors: Zhao
authors: Bao-gui
authors: BG
authors: Sun
authors: Qin-zhu
authors: QZ
authors: Wen
authors: Jian-jun
authors: JJ
authors: Zhang
authors: Wei
authors: W
authors: Jin
authors: Ji-xiang
authors: JX
authors: Xue
authors: Wen-yan
authors: WY
authors: Zhuang
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D054855:Drug-Eluting Stents; D006965:Hyperplasia; D010087:Oxides / Q000008:administration & dosage / Q000494:pharmacology*; D011184:Postoperative Period; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology
chemical_list: D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide